NCT01597388 2026-02-24
AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer
AstraZeneca
Phase 1 Completed
Clinical Trials
26 trialsNCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT02546661 2025-12-29
BISCAY
AstraZeneca
Phase 1 Active not recruiting
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT02398747 2024-12-17
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02216786 2024-12-02
MANTA
Queen Mary University of London
Phase 2 Completed
NCT02193633 2024-09-26
TAX-TORC
Royal Marsden NHS Foundation Trust
Phase 1 Completed
NCT02599714 2024-06-06
PASTOR
AstraZeneca
Phase 1 Completed
NCT02730923 2024-02-13
VICTORIA
Centre Leon Berard
Phase 1/2 Unknown
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT02619864 2023-08-04
mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme
Canadian Cancer Trials Group
Phase 1 Completed
NCT03071874 2022-10-18
Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas
Massachusetts General Hospital
Phase 2 Unknown
NCT03205046 2021-01-06
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
Acerta Pharma BV
Phase 1/2 Terminated
NCT02752204 2020-11-05
TORCH
University of Birmingham
Phase 2 Completed
NCT02583542 2020-02-25
TORCMEK
Queen Mary University of London
Phase 1/2 Unknown
NCT02064608 2019-07-17
CaNCaP02
Cambridge University Hospitals NHS Foundation Trust
Phase 1 Completed
NCT03061708 2019-05-20
AZD2014
Samsung Medical Center
Phase 2 Terminated
NCT03082833 2019-05-20
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
Samsung Medical Center
Phase 2 Terminated
NCT03166176 2019-05-20
TSC1/2_SC
Samsung Medical Center
Phase 2 Withdrawn
NCT03166904 2019-05-20
RICTOR_SC
Samsung Medical Center
Phase 2 Withdrawn
NCT03106155 2018-09-20
[SUKSES-D]
Samsung Medical Center
Phase 2 Terminated
NCT02780830 2016-09-15
INHIBITOR
AstraZeneca
Phase 1 Withdrawn
NCT01026402 2016-02-11
Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014
AstraZeneca
Phase 1 Completed
NCT01793636 2014-06-24
ZEBRA
Queen Mary University of London
Phase 2 Terminated